Swedish Orphan Biovitrum AB (Sobi), which specialises in treatments for rare diseases, reported a 19.8% increase in revenue in 2014 but its loss widened sharply, mainly because of a write-off connected with a product failure. ---Subscribe to MedNous to access this article--- Company News
